Approved for use through 11/30/2011. OMB 0651-0035 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY OR REVOCATION OF POWER OF ATTORNEY WITH A NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS

Application Number	10/576,794
Filing Date	05/24/2007
First Named Inventor	Abdessatar CHTOUROU et al
Title	Virally-Safe Factor VIII with a Low Content of Higher Multimers
Art Unit	1656
Examiner Name	TSAY, MARSHA M.
Attorney Docket Number	096183-0103

I hereby revoke all p	revious powers of atto	orney given in the abo	ve-identified application.	
I hereby appoint:		***************************************		
Practitioners associated with	h the Customer Number;	22428	***************************************	
OR				
Practitioner(s) named below	Α .6			
Name		Re	Registration Number	
	,0000000000000000000000000000000000000			
***************************************	xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx			
	200200000000000000000000000000000000000			
	XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX	***************************************		
as my/our attorney(s) or agent(s Trademark Office connected the	s) to prosecute the application ide erewith.	entified above, and to transact all	business in the United States Patent and	
Please recognize or change the	correspondence address for the a	bove-identified application to:		
	the above-mentioned Customer			
OR The address associated with	- Oritaniar Wirmhair	22428		
OR	1 Customer number.	20000000000000000000000000000000000000		
Firm or Individual Name				
Address				
City		State	Zip	
Country				
Telephone		Email		
I am the:	WATA-440-00-00-00-00-00-00-00-00-00-00-00-00			
Applicant/Inventor.	di ambiri a ma			
Assignee of record of the entire Statement under 37 CFR 3	tire interest. See 37 CFR 3,71. 3,73(b) is enclosed. (Form PT	O/SB/96)		
SIGNATURE of Applicant or Assignee of Record				
Signature:		Date	Dc/10ber 25, 2010	
Name	RECHON CAN		33.469.82; 68 .04	
Title and Company	Chairman & CEO for LFB SA			
NOTE: Signatures of all the inver signature is required, see below*.	ntors or assignees of record of the enti	ire interest or their representative(s) a	re required. Submit multiple forms if more than one	

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.31 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PATENT ASSIGNMENT

WHEREAS Laboratoire Français Du Fractionnement Et Des Biotechnologies (hereinafter "Assignor") is the owner of the following United States Letters Patent(s), and the invention(s) set forth therein, as shown by the records of the United States Patent and Trademark Office:

U.S. PATENT APPLICATION NO or U.S. PATENT NO.	FILING or GRANT DATE	TITLE
10/576,794	05/24/2007	VIRALLY-SAFE FACTOR VIII WITH A LOW CONTENT OF HIGHER MULTIMERS

WHEREAS LFB SA, of 3 Avenue des Tropiques, ZA de Courtaboeuf, 91940 Les Ulis, France, (hereinafter referred to as "Assignee") is desirous of acquiring the full right, title and interest in and to said invention for the United States of America, and in and to said United States Patent Application;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by Assignor, Assignor has sold, assigned, transferred and set over, and by these presents hereby sells, assigns, transfers and sets over to Assignee the entire and exclusive right, title and interest in and to said inventions for the United States of America, and in and to said application for Letters Patent listed above, including any and all divisional, continuation, continuation-in-part, reissues or extensions thereof, to be held and enjoyed by Assignee for its own use as fully and entirely as the same would have been held and enjoyed by Assignor had this assignment not been made; the Commissioner of Patents and Trademarks of the United States of America is hereby authorized to transfer the portion of the title indicated to said application to said Assignee in accordance herewith; this assignment being under covenant, not only that full power to make the same is had by the Assignor, but also that such assigned rights are not encumbered by any grant, license, or other right theretofore given; Assignor hereby undertakes to execute and deliver to Assignee upon request all lawful documents which may be requested by Assignee, and to furnish Assignee with all facts relating to said invention as may be requested.

The undersigned hereby grant the firm of FOLEY & LARDNER LLP, the power to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

Laboratoire Français Du Fractionnement Et Des Biotechnologies

Date: 25/10/10

Name: DECHON Christian

Title: Chairman and CEO

Date: 25/16/10

Date: 254010

Witness:

Witness: